Floatz logo

Asidna

Metastatic Prostate Carcinoma

Valerio TherapeuticsPhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

251 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

Asidna is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →
breast cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →